Anton Lindqvist
Chief Scientific Officer Diamyd Medical
Anton Lindqvist has served as the Chief Scientific Officer at Diamyd Medical since 2017, a company focused on developing disease-modifying therapies for autoimmune diabetes. He possesses more than 20 years of experience in academic research and technological development within Swedish Biotech firms. His previous experience includes research in immunology, virology, biomaterials, and bioprocess technology at esteemed institutions such as Karolinska Institute, Royal Institute of Technology, Swedish Agricultural University, University of Pittsburgh, and Uppsala University. Additionally, he has held developmental positions at Immune Therapy Holdings and Spiber Technologies AB. Mr. Lindqvist holds a Master of Science degree in Biotechnology Engineering from the University of Uppsala. He firmly believes that a cure for autoimmune diabetes is achievable within our life time.
Seminars
- Updates from the ongoing DIAGNODE-3 phase 3 trial, (interim readout expected March, 2026)
- Review of pharmacodynamic effects of rhGAD65 treatment
- Evidence of disease-modifying benefit in Stage 3 Type 1 diabetes and strategy to guide next-phase development and future precision-medicine strategies
NEW DATA
